Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 272-028-3 | CAS number: 68649-42-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- one-generation reproductive toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Justification for type of information:
- Data is from peer reviewed journal
Data source
Reference
- Reference Type:
- publication
- Title:
- A Developmental Toxicity Study in Rats.
- Author:
- WAHEED H. SIDDIQUI et. al.
- Year:
- 1 993
- Bibliographic source:
- FUNDAMENTAL AND APPLIED TOXICOLOGY,1993
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: as mentioned below
- Principles of method if other than guideline:
- Developmental Toxicity Study of Quaternary Silsesquioxane in rats
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride
- EC Number:
- 248-595-8
- EC Name:
- Dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride
- Cas Number:
- 27668-52-6
- Molecular formula:
- C26H58NO3Si.Cl
- IUPAC Name:
- N,N-dimethyl-N-[3-(trimethoxysilyl)propyl]octadecan-1-aminium chloride
- Reference substance name:
- Quaternary Silsesquioxane
- IUPAC Name:
- Quaternary Silsesquioxane
- Test material form:
- other: Liquid
- Details on test material:
- - Name of test material (as cited in study report):Quaternary Silsesquioxane
- Molecular formula (if other than submission substance):C26H58NO3Si.Cl
- Molecular weight (if other than submission substance):496.287 g/mole
- Substance type:Organic
- Physical state:Liquid
Constituent 1
Constituent 2
- Specific details on test material used for the study:
- - Name of test material (as cited in study report):Quaternary Silsesquioxane
- Molecular formula (if other than submission substance):C26H58NO3Si.Cl
- Molecular weight (if other than submission substance):496.287 g/mole
- Substance type:Organic
- Physical state:Liquid
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Details on test animals and env. conditions
TEST ANIMALS
- Source: Charles River Breeding Laboratories, Inc. (Portage, MI).
- Age at study initiation: 13 weeks
- Weight at study initiation: 206 to 275 g at gestation day 0
- Fasting period before study: No data available
- Housing: Animal were housed individually, except during mating, in suspended stainless steel wire mesh cages from receipt until sacrifice.
- Use of restrainers for preventing ingestion (if dermal): No data available
- Diet (e.g. ad libitum): basal laboratory diet of Certified Rodent Chow 5002 (Ralston Purina Co., St. Louis, MO), ad libitum
- Water (e.g. ad libitum): tap water, ad libitum
- Acclimation period: 12 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 17 -20°C
- Humidity (%):Relative humidity: 30-70%
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): 12 hrs
IN-LIFE DATES: From: To: No data available
Administration / exposure
- Route of administration:
- oral: gavage
- Type of inhalation exposure (if applicable):
- not specified
- Vehicle:
- corn oil
- Details on exposure:
- Details on oral exposure
PREPARATION OF DOSING SOLUTIONS: Quat-Silsesquioxane was suspended fresh daily in corn oil
DIET PREPARATION
- Rate of preparation of diet (frequency): No data available
- Mixing appropriate amounts with (Type of food): No data available
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water): corn oil.
- Concentration in vehicle: 0, 100, 300, and 1000 mg/kg/day
- Amount of vehicle (if gavage): 10 ml/kg.
- Lot/batch no. (if required): No data available
- Purity: No data available - Details on mating procedure:
- - M/F ratio per cage:1:1
- Length of cohabitation:No data available
- Proof of pregnancy: [vaginal plug / sperm in vaginal smear] referred to as [day 0 / day 1] of pregnancy:Copulatory plug referred to as 0 of pregnancy
- After ... days of unsuccessful pairing replacement of first male by another male with proven fertility.:No data available
- Further matings after two unsuccessful attempts: No data available
- After successful mating each pregnant female was caged (how):stainless steel wire mesh cages: Individually
- Any other deviations from standard protocol:No data available - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 10 days
- Frequency of treatment:
- Daily from gestation days 6 to 15
- Details on study schedule:
- No data available
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day
- Dose / conc.:
- 100 mg/kg bw/day
- Dose / conc.:
- 300 mg/kg bw/day
- Dose / conc.:
- 1 000 mg/kg bw/day
- No. of animals per sex per dose:
- Total: 100
0 mg/kg bw: 25 female
100 mg/kg bw: 25 female
300 mg/kg bw: 25 female
1000 mg/kg bw: 25 female - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dosage levels were selected from the results obtained in a range-finding developmental toxicity study. In that study neither maternalnor developmental toxicity was seen at dosage levels of up to 1000 mg/kg/day.
- Rationale for animal assignment (if not random): Mated females were assigned consecutively, in the order the mating was detected
- Rationale for selecting satellite groups: No data available
- Post-exposure recovery period in satellite groups:No data available
- Section schedule rationale (if not random):No data available - Positive control:
- No data available
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
- Cage side observations checked in table [No.?] were included. For changes in appearance, behavior and mortality.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: twice daily
BODY WEIGHT: Yes
- Time schedule for examinations: daily on Gestation Days 0,6,9, 12, 16, and 20.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time weighted averages from the consumption and body weight gain data: No data available
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data available
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data available
- Time schedule for examinations: No data available
other:
organ weight: liver and gravid uterine weight was recorded - Oestrous cyclicity (parental animals):
- Nongravid Uteri were examined for Corpora lutea, Total implantation and Postimplantation loss.
- Sperm parameters (parental animals):
- No data available
- Litter observations:
- viable fetuses, crown-rump length, fetal body weight and sex ratio were examined.
- Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: No data available
- Maternal animals: Yes, gross pathology were examined. - Postmortem examinations (offspring):
- Postmortem examinations (offspring)
SACRIFICE: Yes
GROSS NECROPSY: Yes
HISTOPATHOLOGY: Yes
One-half of the fetuses were examined for soft tissue and remaining half for subsequent skeletal examination. - Statistics:
- 1)Mean maternal body weights and liver weights, maternal feed consumption, numbers of corpora lutea, total implantations, live fetuses, gravid uterine weight, and mean fetal body weights were compared by one-way analysis of variance (ANOVA), Bartlett's test for homogeneity of variance, and the appropriate test for equal and unequal variance (Steel and Torrie, 1960) using Dunnett's multiple comparison.
2) The proportions of resorbed and dead fetuses and postimplantation losses were compared by the Mann-Whitney t/test.
3) Male to female fetal sex ratios and the proportions of litters with malformations and developmental variations were compared using the x1 test criterion with Yate's correction for 2 X 2 contingency tables and/or
Fisher's exact probability test. - Reproductive indices:
- Fertility and gestation were examined.
- Offspring viability indices:
- yes, viable fetuses were examined.
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical signs changes were observed in treated female rats as compared to control.
- Dermal irritation (if dermal study):
- not specified
- Mortality:
- no mortality observed
- Description (incidence):
- No maternal mortality were observed in treated female rats as compared to control.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No effect on body weight were observed in treated female rats as compared to control.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No effect on feed consumption changes were observed in treated female rats as compared to control.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- No clinical signs or behavioral changes were observed in treated female rats as compared to control.
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not specified
- Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- No adverse effects on mean number of corpora lutea, number of live fetuses per litter, litter size, mean fetal body weight, or mean crown-rump length.
Ratio of male and female pups at the 1000 mg/ kg/day dose level was significantly different from the control group but was not considered treatment related.
Effect levels (P0)
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- clinical signs
- mortality
- body weight and weight gain
- food consumption and compound intake
- organ weights and organ / body weight ratios
- reproductive performance
- other: No effect observed
Target system / organ toxicity (P0)
- Critical effects observed:
- not specified
- System:
- other: not specified
- Organ:
- not specified
- Treatment related:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- not specified
- Mortality / viability:
- no mortality observed
- Description (incidence and severity):
- No effect on viability were observed in treated fetuses as compared to control.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No effect on fetal body weight fetuses were observed as compared to control.
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No external malformations were observed in treated fetuses as compared to control.
- Histopathological findings:
- no effects observed
- Description (incidence and severity):
- One fetus with bent limb bones, two fetuses from different mothers with microphthalmia and two other fetuses with omphalocele were observed at 1000 mg/kg/day and single fetus with multiple malformations were observed at 300 mg/kg/day in treated fetuses as compared to control. The incidence of developmental variations in the treated litters was not significantly increased over the control incidence. They occurred in low frequency and were distributed randomly across the Quat-Silsesquioxanetreated and control groups.
- Other effects:
- not specified
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not specified
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not specified
Effect levels (F1)
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- viability
- mortality
- body weight and weight gain
- gross pathology
- histopathology: non-neoplastic
- other: No effect observed.
Target system / organ toxicity (F1)
- Critical effects observed:
- not specified
- System:
- other: not specified
- Organ:
- not specified
- Treatment related:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
- Treatment related:
- not specified
- Relation to other toxic effects:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Any other information on results incl. tables
TABLE 1
Summary of Maternal Body Weight Gain, Food Consumption, and Liver Weights
|
Dose levels (mg/kg/day) |
||||
Gestation day |
0 |
100 |
300 |
1000 |
|
|
Mean body weight change (g) |
||||
0-6 |
26 ± 7a |
25 ±7 |
27 ±7 |
29 ±8 |
|
6-9 |
3 ± 8 |
3 ± 8 |
7±7 |
6 ± 8 |
|
9-12 |
16 ± 10 |
19 ±6 |
15 ± 4 |
15 ± 9 |
|
12-16 |
27 + 7 |
26 ± 12 |
22 ± 8 |
22 ± 11 |
|
16-20 |
59 ± 11 |
61 ± 17 |
62 ± 13 |
60 ± 15 |
|
0-20 |
131 ± 19 |
133 ±25 |
132 ± 19 |
132 ±25 |
|
0-20 adjustedb |
61 + 13 |
62 ± 14 |
62+13 |
66 ± 13 |
|
Mean food consumption (g/dam/day) |
|||||
0-6 |
21.5 + 2 |
21.5 ±2 |
22.3 ±2 |
22.0 ± 4 |
|
6-9 |
17.8 ± 4 |
15.2 ±3* |
17.9 ± 3 |
19.9 ± 8 |
|
9-12 |
17.9 ± 2 |
17.9 ± 2 |
19.9 ±3* |
21.2 ±8 |
|
12-16 |
19.8 ± 2 |
21.1 ±5 |
20.4 ± 3 |
20.2 ±4 |
|
16-20 |
27.3 ± 2 |
27.4 ±3 |
26.2 ±6 |
28.0 ±2 |
|
0-20 |
21.3+1 |
21.2 ± 2 |
21.7 ± 2 |
22.5 ± 3 |
|
Mean maternal liver weight(20 days of gestation) |
|||||
Absolute (g) |
15.4 + 2.9 |
15.3 ±2.9 |
16.1 ±2.6 |
16.5 ±2.5 |
|
Relative (%) |
4.4 ± 0.4 |
4.4 ± 0.3 |
4.5 ±0.3 |
4.6 ± 0.2* |
|
aMean ± SD.
bDam body weight minus the uterus and its contents.
* Significantly different from controls; ANOVA, Welch Test, P < 0.05
TABLE 2
Summary of Observations at Time of Cesarean Sections
|
Dose levels (mg/kg/day) |
|||
|
0 |
100 |
300 |
1000 |
Animals examined at cesarean sections |
25 |
25 |
25 |
25 |
Nongravid |
7 |
7 |
5 |
4 |
Gravid |
18 |
18 |
20 |
21 |
Dams with resorptions only |
0 |
0 |
0 |
0 |
Dams with viable fetuses |
18 |
18 |
20 |
21 |
Viable fetuses/dama |
13.3 ±2.7 |
13.3 ± 3.3 |
13.2 ± 4.2 |
12.4 ± 4.0 |
Postimplantation loss/dama |
1.1 ±0.8 |
0.6 ± 0.61 |
1 5 ± 2.31 |
0.8 + 0.8 |
Total implantation/dama |
14.4 ±2.5 |
13.9 ± 3.5 |
14.7 ± 3.4 |
13.2 ± 4.4 |
Corpora lutea/dama |
17.8 ±3.3 |
15.8 ± 2.6 |
17.7 ± 2.9 |
16.2 ± 3.2 |
Mean crown-rump length (cm) |
3.5 ±0.1 |
3.5 ± 0.2 |
3.5 ± 0 1 |
3.5 ± 0 1 |
Group mean uterine weights (g) |
70.1 ±14.1 |
71.3 ±17.7 |
70.3 ±21.2 |
66.5 ± 18.2 |
Group mean preimplantation loss (%) |
18.8 |
12.0 |
17.2 |
18.2 |
Group mean postimplantation loss (%) |
7.7 |
4.4 |
9.9 |
6.1 |
Mean fetal body weight (g) |
3.4 ±0.2 |
3.5 ± 0.5 |
3.4 ± 0.2 |
3.4 + 0.3 |
Fetal sex ratio—m:f (%) |
44:56 |
49:51 |
50:50 |
55:45* |
aMean ± SD.
* Significantly different; x2. P * 0.05.
TABLE 3
Summary of the Incidence of Fetal Malformations*
|
Dose levels (mg/kg/day) |
|||
|
No. examined |
|||
Litters |
18 |
18 |
20 |
21 |
Fetuses externally |
240 |
238 |
263 |
260 |
Fetuses viscerally |
119 |
118 |
132 |
129 |
Fetuses skeletally |
121 |
121 |
132 |
132 |
|
No.of fetuses (No. Of litters) affected |
|||
Malformations observed |
|
|
|
|
Anophthalmia |
1 (1) |
|
|
|
Microphthalmia |
|
|
|
2(2) |
Gastroschisis |
|
|
1(1) |
|
Omphalocele |
|
|
|
2(2) |
Tail agenesis |
|
|
1(1) |
|
Tarsal flexure |
|
|
1(1) |
|
Edema |
|
|
1(1) |
|
Malformed skull bones |
|
|
1(1) |
|
Bent clavicle |
|
|
1(1) |
|
Bent scapula |
|
|
1(1) |
|
Amelia |
|
|
1(1) |
|
Micromelia |
|
|
1(1) |
|
Bent limb bones |
1(1) |
|
|
1(1) |
Vertebral agenesis |
|
|
1(1) |
|
Pelvic malformation |
|
|
1(1) |
|
Total fetuses (litters) with malformations |
2(2) |
0(0) |
1(1) |
5(4) |
* No statistical significance was observed.
TABLE 4
Summary of the Incidence of Fetal Variations*
|
Summary of the Incidence of Fetal Variations* |
|||
|
Dose levels (mg/kg/day) |
|||
|
0 |
100 |
300 |
1000 |
|
No. examined |
|||
Litters |
18 |
18 |
20 |
21 |
Fetuses externally |
240 |
238 |
263 |
260 |
Fetuses viscerally |
119 |
118 |
132 |
129 |
Fetuses skeletally |
121 |
121 |
132 |
132 |
|
No.of fetuses (No. Of litters) affected |
|||
Developmental variations observed |
|
|
|
|
Renal papillae not developed |
|
1(1) |
1(1) |
|
Distended ureter |
|
1(1) |
1(1) |
|
Skull reduced in ossification |
2(1) |
3(2) |
2(2) |
|
Hyoid unossified |
1(1) |
|
1(1) |
1(1) |
25 presacral vertebrae |
|
|
1(1) |
2(2) |
Greater than 13 pairs of full ribs |
|
|
2(2) |
|
14th rudimentary rib(s) |
6(3) |
7(4) |
12(5) |
6(5) |
Bent ribs |
|
1(1) |
|
2(1) |
7th cervical rib |
3(3) |
|
2(2) |
|
Vertebrae reduced in ossification |
1(1) |
|
1(1) |
|
Misaligned sternebra(e) |
8(6) |
6(5) |
8(6) |
4(3) |
Sternebra 5 and/or 6 unossified |
3(5) |
7(6) |
4(4) |
8(6) |
Other sternebra(e) unossified |
1(1) |
|
1(1) |
1(1) |
Ischia reduced in ossification |
1(1) |
|
|
2(1) |
Total fetuses (litters) with developmental variations |
22(12) |
24(11) |
30(14) |
22(12) |
* No statistical significance was observed.
Applicant's summary and conclusion
- Conclusions:
- NOAEL was considered to be 300 mg/kg bw for P generation and 1000 mg/kg for F1 generation when Sprague-Dawleyd female rats were treated with Quat-Silsesquioxane orally by gavage from day 6 to 15 of gestation.
- Executive summary:
In a developmental toxicity study, Sprague-Dawley female rats were treated with Quat-Silsesquioxane in the concentration of 0, 100, 300, or 1000 mg/kg/day orally by gavage in corn oil.No maternal mortality and clinical signs or behavioral changes were observed in treated female rats as compared to control. No effect on body weight and feed consumption changes were observed in treated female rats as compared to control. Similarly, no effect on reproductive parameters such as number of corpora lutea, number of live fetuses per litter, litter size, mean fetal body weight, or mean crown-rump length was observed in treated rats. Ratio of male and female pups at the 1000 mg/ kg/day dose level was significantly different from the control group but was not considered treatment related. Slight but significant increase in relative liver weight of treated female rats was observed as compared to control. In addition, No effect on viability, fetal body weight and external malformations were observed in treated fetuses as compared to control. One fetus with bent limb bones, two fetuses from different mothers with microphthalmia and two other fetuses with omphalocele were observed at 1000 mg/kg/day and single fetus with multiple malformations were observed at 300 mg/kg/day in treated fetuses as compared to control. The incidence of developmental variations in the treated litters was not significantly increased over the control incidence. They occurred in low frequency and were distributed randomly across the Quat-Silsesquioxane treated and control groups. Therefore,NOAEL was considered to be 300 mg/kg bw for P generation and 1000 mg/kg for F1 generation when Sprague-Dawley female rats were treated with Quat-Silsesquioxane orally by gavage from day 6 to 15 of gestation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.